CA3163243A1 - Sstr5 antagonists - Google Patents
Sstr5 antagonistsInfo
- Publication number
- CA3163243A1 CA3163243A1 CA3163243A CA3163243A CA3163243A1 CA 3163243 A1 CA3163243 A1 CA 3163243A1 CA 3163243 A CA3163243 A CA 3163243A CA 3163243 A CA3163243 A CA 3163243A CA 3163243 A1 CA3163243 A1 CA 3163243A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- pharmaceutically acceptable
- prodrug
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/205—Radicals derived from carbonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6509—Six-membered rings
- C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943099P | 2019-12-03 | 2019-12-03 | |
| US62/943,099 | 2019-12-03 | ||
| PCT/US2020/062890 WO2021113362A1 (en) | 2019-12-03 | 2020-12-02 | Sstr5 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3163243A1 true CA3163243A1 (en) | 2021-06-10 |
Family
ID=76221934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3163243A Pending CA3163243A1 (en) | 2019-12-03 | 2020-12-02 | Sstr5 antagonists |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20230041621A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP4073075A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023516235A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115380036A (cg-RX-API-DMAC7.html) |
| AR (1) | AR120652A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020398874A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163243A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202134248A (cg-RX-API-DMAC7.html) |
| UY (1) | UY38976A (cg-RX-API-DMAC7.html) |
| WO (3) | WO2021113363A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ,インク. | Gpr119アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| CA3227879A1 (en) * | 2021-07-30 | 2023-02-02 | TAE Life Sciences | Borylated amino acid compositions comprising bts and bts(ome) for use in boron neutron capture therapy and methods thereof |
| CN116789570B (zh) * | 2022-03-14 | 2026-01-27 | 长沙理工大学 | 磺酰胺脱氨制备磺酸衍生物的方法 |
| WO2024204277A1 (ja) | 2023-03-27 | 2024-10-03 | 株式会社スコヒアファーマ | 成長ホルモン分泌促進剤 |
| WO2025158275A1 (en) | 2024-01-24 | 2025-07-31 | Pfizer Inc. | Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds |
| TW202606664A (zh) * | 2024-04-19 | 2026-02-16 | 美商美國禮來大藥廠 | 升糖素受體促效劑及其作為療法之用途 |
| WO2025222000A1 (en) * | 2024-04-19 | 2025-10-23 | Eli Lilly And Company | Substituted 1,1'-biphenyl compounds as glucagon receptor agonists |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0214967A (pt) * | 2001-12-14 | 2005-05-10 | Novo Nordisk As | Composto, sal famaceuticamente aceitável, processo para a preparação de um composto, composição farmacêutica, uso de um composto e método de tratar um distúrbio de um paciente |
| ATE521610T1 (de) * | 2003-09-10 | 2011-09-15 | Virochem Pharma Inc | Spiroverbindungen und -verfahren zur modulation von chemokin-rezeptor-aktivität |
| US7709642B2 (en) * | 2004-06-25 | 2010-05-04 | Virochem Pharma, Inc. | Spirohydantoin compounds and methods for the modulation of chemokine receptor activity |
| CA2615656A1 (en) * | 2005-07-18 | 2007-01-25 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| KR101117931B1 (ko) * | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 페닐, 피리딘 및 퀴놀린 유도체 |
| WO2008030412A2 (en) * | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| TW201006816A (en) * | 2008-05-15 | 2010-02-16 | Organon Nv | Hexafluoroisopropanol derivatives |
| WO2010129729A1 (en) * | 2009-05-07 | 2010-11-11 | Merck Sharp & Dohme Corp. | Substituted spirocyclic amines useful as antidiabetic compounds |
| WO2011142359A1 (ja) * | 2010-05-10 | 2011-11-17 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| JP2013529210A (ja) * | 2010-05-18 | 2013-07-18 | メルク・シャープ・エンド・ドーム・コーポレイション | Sstr5アンタゴニストとしてのスピロイソオキサゾリン化合物 |
| US8742110B2 (en) * | 2010-08-18 | 2014-06-03 | Merck Sharp & Dohme Corp. | Spiroxazolidinone compounds |
| TW201712012A (zh) * | 2015-06-16 | 2017-04-01 | 美國禮來大藥廠 | 2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物 |
| WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
-
2020
- 2020-12-02 EP EP20896919.6A patent/EP4073075A4/en not_active Withdrawn
- 2020-12-02 CN CN202080095492.0A patent/CN115380036A/zh active Pending
- 2020-12-02 CA CA3163243A patent/CA3163243A1/en active Pending
- 2020-12-02 AU AU2020398874A patent/AU2020398874A1/en not_active Abandoned
- 2020-12-02 EP EP20895270.5A patent/EP4069708A4/en not_active Withdrawn
- 2020-12-02 WO PCT/US2020/062891 patent/WO2021113363A1/en not_active Ceased
- 2020-12-02 WO PCT/US2020/062898 patent/WO2021113368A1/en not_active Ceased
- 2020-12-02 JP JP2022529942A patent/JP2023516235A/ja active Pending
- 2020-12-02 US US17/782,361 patent/US20230041621A1/en not_active Abandoned
- 2020-12-02 UY UY0001038976A patent/UY38976A/es not_active Application Discontinuation
- 2020-12-02 EP EP20895271.3A patent/EP4069702A4/en not_active Withdrawn
- 2020-12-02 WO PCT/US2020/062890 patent/WO2021113362A1/en not_active Ceased
- 2020-12-02 US US17/782,438 patent/US20230113609A1/en not_active Abandoned
- 2020-12-02 AR ARP200103345A patent/AR120652A1/es unknown
- 2020-12-02 US US17/782,370 patent/US20230050965A1/en not_active Abandoned
- 2020-12-03 TW TW109142680A patent/TW202134248A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20230113609A1 (en) | 2023-04-13 |
| EP4069702A4 (en) | 2023-12-27 |
| EP4069702A1 (en) | 2022-10-12 |
| EP4069708A1 (en) | 2022-10-12 |
| TW202134248A (zh) | 2021-09-16 |
| EP4073075A1 (en) | 2022-10-19 |
| WO2021113368A1 (en) | 2021-06-10 |
| US20230050965A1 (en) | 2023-02-16 |
| EP4073075A4 (en) | 2023-12-27 |
| AR120652A1 (es) | 2022-03-09 |
| US20230041621A1 (en) | 2023-02-09 |
| WO2021113363A1 (en) | 2021-06-10 |
| CN115380036A (zh) | 2022-11-22 |
| UY38976A (es) | 2021-06-30 |
| JP2023516235A (ja) | 2023-04-19 |
| WO2021113362A1 (en) | 2021-06-10 |
| AU2020398874A1 (en) | 2022-06-23 |
| EP4069708A4 (en) | 2024-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4073075A1 (en) | Sstr5 antagonists | |
| US12264171B2 (en) | GPR40 agonists | |
| TW202227397A (zh) | 雙環的-雜環衍生物及相關用途 | |
| EP4041722A1 (en) | Gpr119 agonists | |
| CA3173732A1 (en) | Gpr40 agonists | |
| EP3976576A1 (en) | Gpr40 agonists | |
| MX2010012492A (es) | Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4. | |
| TW202543613A (zh) | 作為glp-1r激動劑的新型化合物及其用途 | |
| AU2023327885A1 (en) | Methods of manufacturing kinase inhibitors | |
| WO2025062330A1 (en) | Heterocyclic compounds as cbp selective degraders | |
| TW202542163A (zh) | 作為glp-1r激動劑的新型化合物及其用途 | |
| CA3183575A1 (en) | Ampk activators | |
| CN119384412A (zh) | Sarm1调节剂、其制备和用途 | |
| EP4320129A1 (en) | Gpr119 agonists | |
| WO2023097189A1 (en) | Ampk activators | |
| WO2023097190A1 (en) | Ampk activators | |
| WO2025136929A1 (en) | Gpr40 agonists | |
| CN119490501A (zh) | 咪唑双环化合物及其制备方法和用途 | |
| HK40032239B (en) | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof | |
| KR20220118267A (ko) | Fxr 작용제로서 아자바이사이클로알킬 유도체 화합물 및 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250825 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20251027 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251231 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260113 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260202 |
|
| B12 | Application deemed to be withdrawn, abandoned or lapsed |
Free format text: ST27 STATUS EVENT CODE: N-6-6-B10-B12-B301 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO A REQUEST FOR EXAMINATION NOTICE Effective date: 20260402 |
|
| U13 | Renewal or maintenance fee not paid |
Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE Effective date: 20260602 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260703 |